Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging

Molecular Imaging

Volumn 10, Issue 3, 2011, Pages 153-167

  Kim, Hyunki ^a   Folks, Karri D ^a   Guo, Lingling ^a   Sellers, Jeffery C ^a   Fineberg, Naomi S ^a   Stockard, Cecil R ^a   Grizzle, William E ^a   Buchsbaum, Donald J ^a   Morgan, Desiree E ^a   George, James F ^a   Zinn, Kurt R ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLUMINESCENCE IMAGING; CETUXIMAB; CLINICAL USE; DCE-MRI; DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING; EPIDERMAL GROWTH FACTOR RECEPTORS; HISTOLOGIC ANALYSIS; IRINOTECAN; MICROVESSEL DENSITY; ORTHOTOPIC; PANCREATIC ADENOCARCINOMA; PANCREATIC CANCERS; PANCREATIC TUMORS; PHOSPHATE-BUFFERED SALINES; PROLIFERATING CELLS; SIGNAL CHANGES; TUMOR VOLUMES;

BIOLOGICAL MATERIALS; BIOLUMINESCENCE; CHEMOTHERAPY; DISEASES; RESONANCE; TUMORS;

MAGNETIC RESONANCE IMAGING;

CAMPTOTHECIN; CETUXIMAB; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; IRINOTECAN; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG SCREENING; HUMAN; METHODOLOGY; MOUSE; MOUSE MUTANT; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; CAMPTOTHECIN; CELL LINE, TUMOR; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, SCID; PANCREATIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955003047     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2010.00040     Document Type: Article

References (41)

1. Presentation from the American Cancer Society (Cancer Statistics, 2009) Available at: http://www.cancer.org/docroot/PRO/content/PRO-1-1-Cancer- Statistics-2009-presentation.asp (Accessed on December 8, 2009).
2. Wray CJ, Ahmad SA, Matthews JB, et al. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 2005;128:1626-41. (Pubitemid 40692556)
3. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
4. Loehrer PJ, Powell ME, Cardenes HR, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008;26 Suppl:4506.
5. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20: 3270-5. (Pubitemid 34831525)
6. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52. (Pubitemid 46630743)
7. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83. (Pubitemid 41095218)
8. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23: 3509-16.
9. Tobita K, Kijima H, Dowaki S, et al. Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 2003;11:305-9.
10. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004;22:2610-6. (Pubitemid 41103748)
11. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGFalpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32. (Pubitemid 28280548)
12. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6. (Pubitemid 46972777)
13. Chhieng DC, Jhala D, Jhala N, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy: a study of 103 cases. Cancer 2002;96: 232-9. (Pubitemid 34920140)
14. Evelhoch JL, Gillies RJ, Karczmar GS, et al. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2000;2:152-65. (Pubitemid 30123186)
15. Desjardins A, Barboriak DP, Herndon JE, et al. Dynamic contrastenhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). J Clin Oncol 2007;25 Suppl:2029.
16. Cheung YC, Chen SC, Su MY, et al. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 2003;78:51-8.
17. Martincich L, Montemurro F, De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 2004;83:67-76. (Pubitemid 38141894)
18. Baba Y, Furusawa M, Murakami R, et al. Role of dynamic MRI in the evaluation of head and neck cancers treated with radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:783-7. (Pubitemid 27181309)
19. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-64. (Pubitemid 46606209)
20. Rosen MA, Schnall MD. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 2007;13:770s-6s.
21. Kim H, Morgan DE, Buchsbaum DJ, et al. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res 2008;68:8369-76.
22. Abrams MJ, Juweid M, tenKate CI, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990;31:2022-8.
23. Larsen SK, Solomon HF, Caldwell G, et al. [99mTc]tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates. Bioconjug Chem 1995;6:635-8.
24. Lowry O, Rosebrough N, Farr L, et al. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
25. Yankeelov TE, Luci JJ, Lepage M, et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging 2005;23:519-29. (Pubitemid 40779238)
26. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32. (Pubitemid 29463104)
27. Yankeelov TE, Cron GO, Addison CL, et al. Comparison of a reference region model with direct measurement of an AIF in the analysis of DCE-MRI data. Magn Reson Med 2007;57:353-61. (Pubitemid 46214538)
28. Pezold JC, Zinn K, Talbert MA, et al. Validation of ultrasonography to evaluate murine orthotopic oral cavity tumors. ORL J Otorhinolaryngol Relat Spec 2006;68:159-63.
29. Sternberg SR. Biomedical image processing. IEEE Computer 1983; 16:22-34.
30. Hertzog C, Rovine M. Repeated-measures analysis of variance in developmental research: selected issues. Child Dev 1985;56: 787-809.
31. Neter J, Kutner MH, Nachtsheim JC, et al. Applied linear statistical models. 4th ed. Columbus, OH: The McGraw-Hill Companies; 1996.
32. Sokal RR, Rohlf FJ. Biometry: the principles and practice of statistics in biological research. New York: W.H. Freeman; 1995.
33. Rodgers JL, Nicewander WA. Thirteen ways to look at the correlation coefficient. American Statistician 1988;42:59-66.
34. Hosoki T. Dynamic CT of pancreatic tumors. AJR Am J Roentgenol 1983;140:959-65. (Pubitemid 13134190)
35. Morgan DE, Kim H, Ng T, et al. Quantitative perfusion and diffusion-weighted MR imaging of pancreatic adenocarcinoma at 3T: a pilot study. AJR Am J Roentgenol 2009;192:A49-52.
36. Yankeelov TE, DeBusk LM, Billheimer DD, et al. Repeatability of a reference region model for analysis of murine DCE-MRI data at 7T. J Magn Reson Imaging 2006;24:1140-7. (Pubitemid 44658253)
37. Kiessling F, Farhan N, Lichy MP, et al. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia 2004;6: 213-23. (Pubitemid 38657077)
38. Niermann KJ, Fleischer AC, Huamani J, et al. Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrastenhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 2007;26: 749-56. (Pubitemid 46870342)
39. Carano RA, Ross AL, Ross J, et al. Quantification of tumor tissue populations by multispectral analysis. Magn Reson Med 2004;51: 542-51. (Pubitemid 38298668)
40. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004;40: 802-20. (Pubitemid 38519759)
41. Grobner T, Prischl FC. Gadolinium and nephrogenic systemic fibrosis. Kidney Int 2007;72:260-4. (Pubitemid 47172383)